IL300110A - Chiral synthesis of fused bicyclic raf inhibitors - Google Patents

Chiral synthesis of fused bicyclic raf inhibitors

Info

Publication number
IL300110A
IL300110A IL300110A IL30011023A IL300110A IL 300110 A IL300110 A IL 300110A IL 300110 A IL300110 A IL 300110A IL 30011023 A IL30011023 A IL 30011023A IL 300110 A IL300110 A IL 300110A
Authority
IL
Israel
Prior art keywords
cyclics
compressed
chiral synthesis
raf inhibitors
raf
Prior art date
Application number
IL300110A
Other languages
English (en)
Hebrew (he)
Original Assignee
Jazz Pharmaceuticals Ireland Ltd
Priority date (The priority date is an assumption and is not a legal conclusion. Google has not performed a legal analysis and makes no representation as to the accuracy of the date listed.)
Filing date
Publication date
Application filed by Jazz Pharmaceuticals Ireland Ltd filed Critical Jazz Pharmaceuticals Ireland Ltd
Publication of IL300110A publication Critical patent/IL300110A/en

Links

Classifications

    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D471/00Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00
    • C07D471/02Heterocyclic compounds containing nitrogen atoms as the only ring hetero atoms in the condensed system, at least one ring being a six-membered ring with one nitrogen atom, not provided for by groups C07D451/00 - C07D463/00 in which the condensed system contains two hetero rings
    • C07D471/04Ortho-condensed systems
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K31/00Medicinal preparations containing organic active ingredients
    • A61K31/33Heterocyclic compounds
    • A61K31/395Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins
    • A61K31/435Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom
    • A61K31/4353Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems
    • A61K31/4375Heterocyclic compounds having nitrogen as a ring hetero atom, e.g. guanethidine or rifamycins having six-membered rings with one nitrogen as the only ring hetero atom ortho- or peri-condensed with heterocyclic ring systems the heterocyclic ring system containing a six-membered ring having nitrogen as a ring heteroatom, e.g. quinolizines, naphthyridines, berberine, vincamine
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61KPREPARATIONS FOR MEDICAL, DENTAL OR TOILETRY PURPOSES
    • A61K45/00Medicinal preparations containing active ingredients not provided for in groups A61K31/00 - A61K41/00
    • A61K45/06Mixtures of active ingredients without chemical characterisation, e.g. antiphlogistics and cardiaca
    • AHUMAN NECESSITIES
    • A61MEDICAL OR VETERINARY SCIENCE; HYGIENE
    • A61PSPECIFIC THERAPEUTIC ACTIVITY OF CHEMICAL COMPOUNDS OR MEDICINAL PREPARATIONS
    • A61P35/00Antineoplastic agents
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/22Organic complexes
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J31/00Catalysts comprising hydrides, coordination complexes or organic compounds
    • B01J31/16Catalysts comprising hydrides, coordination complexes or organic compounds containing coordination complexes
    • B01J31/24Phosphines, i.e. phosphorus bonded to only carbon atoms, or to both carbon and hydrogen atoms, including e.g. sp2-hybridised phosphorus compounds such as phosphabenzene, phosphole or anionic phospholide ligands
    • B01J31/2404Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring
    • B01J31/2409Cyclic ligands, including e.g. non-condensed polycyclic ligands, the phosphine-P atom being a ring member or a substituent on the ring with more than one complexing phosphine-P atom
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/02Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings
    • C07D405/04Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing two hetero rings directly linked by a ring-member-to-ring-member bond
    • CCHEMISTRY; METALLURGY
    • C07ORGANIC CHEMISTRY
    • C07DHETEROCYCLIC COMPOUNDS
    • C07D405/00Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom
    • C07D405/14Heterocyclic compounds containing both one or more hetero rings having oxygen atoms as the only ring hetero atoms, and one or more rings having nitrogen as the only ring hetero atom containing three or more hetero rings
    • BPERFORMING OPERATIONS; TRANSPORTING
    • B01PHYSICAL OR CHEMICAL PROCESSES OR APPARATUS IN GENERAL
    • B01JCHEMICAL OR PHYSICAL PROCESSES, e.g. CATALYSIS OR COLLOID CHEMISTRY; THEIR RELEVANT APPARATUS
    • B01J2531/00Additional information regarding catalytic systems classified in B01J31/00
    • B01J2531/80Complexes comprising metals of Group VIII as the central metal
    • B01J2531/82Metals of the platinum group
    • B01J2531/821Ruthenium

Landscapes

  • Chemical & Material Sciences (AREA)
  • Organic Chemistry (AREA)
  • Health & Medical Sciences (AREA)
  • Life Sciences & Earth Sciences (AREA)
  • General Health & Medical Sciences (AREA)
  • Chemical Kinetics & Catalysis (AREA)
  • Veterinary Medicine (AREA)
  • Medicinal Chemistry (AREA)
  • Pharmacology & Pharmacy (AREA)
  • Public Health (AREA)
  • Animal Behavior & Ethology (AREA)
  • Inorganic Chemistry (AREA)
  • Materials Engineering (AREA)
  • Epidemiology (AREA)
  • Engineering & Computer Science (AREA)
  • General Chemical & Material Sciences (AREA)
  • Nuclear Medicine, Radiotherapy & Molecular Imaging (AREA)
  • Pharmaceuticals Containing Other Organic And Inorganic Compounds (AREA)
  • Nitrogen Condensed Heterocyclic Rings (AREA)
  • Nitrogen And Oxygen Or Sulfur-Condensed Heterocyclic Ring Systems (AREA)
  • Plural Heterocyclic Compounds (AREA)
  • Medicines That Contain Protein Lipid Enzymes And Other Medicines (AREA)
IL300110A 2020-07-28 2021-07-28 Chiral synthesis of fused bicyclic raf inhibitors IL300110A (en)

Applications Claiming Priority (2)

Application Number Priority Date Filing Date Title
US202063057531P 2020-07-28 2020-07-28
PCT/EP2021/071219 WO2022023450A1 (en) 2020-07-28 2021-07-28 Chiral synthesis of fused bicyclic raf inhibitors

Publications (1)

Publication Number Publication Date
IL300110A true IL300110A (en) 2023-03-01

Family

ID=77564067

Family Applications (1)

Application Number Title Priority Date Filing Date
IL300110A IL300110A (en) 2020-07-28 2021-07-28 Chiral synthesis of fused bicyclic raf inhibitors

Country Status (10)

Country Link
US (2) US20220041595A1 (https=)
EP (1) EP4188923A1 (https=)
JP (1) JP7832924B2 (https=)
KR (1) KR20230058630A (https=)
CN (1) CN116348465B (https=)
AU (1) AU2021318923A1 (https=)
CA (1) CA3187393A1 (https=)
IL (1) IL300110A (https=)
MX (1) MX2023001274A (https=)
WO (1) WO2022023450A1 (https=)

Families Citing this family (4)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
JP2023535790A (ja) 2020-07-28 2023-08-21 ジャズ ファーマシューティカルズ アイルランド リミテッド 縮合二環式raf阻害薬及びその使用方法
CN114921508B (zh) * 2022-07-22 2022-10-11 常熟药明康德新药开发有限公司 (r)-6-羟基色满-3-羧酸的生物催化制备方法
JP2025539426A (ja) 2022-11-29 2025-12-05 ジャズ ファーマシューティカルズ アイルランド リミテッド (s)-5-((3-(4-(4-フルオロフェニル)-1h-イミダゾール-2-イル)クロマン-6-イル)オキシ)-3,4-ジヒドロ-1,8-ナフチリジン-2(1h)-オンの結晶形態
EP4665725A2 (en) * 2023-02-17 2025-12-24 Jazz Pharmaceuticals Ireland Limited Methods of treating solid tumors with mitogen activated protein kinase (mapk) pathway alterations

Family Cites Families (27)

* Cited by examiner, † Cited by third party
Publication number Priority date Publication date Assignee Title
US3932657A (en) 1973-11-12 1976-01-13 The United States Of America As Represented By The United States Energy Research And Development Administration Liposome encapsulation of chelating agents
GB1575343A (en) 1977-05-10 1980-09-17 Ici Ltd Method for preparing liposome compositions containing biologically active compounds
US4235871A (en) 1978-02-24 1980-11-25 Papahadjopoulos Demetrios P Method of encapsulating biologically active materials in lipid vesicles
US4452747A (en) 1982-03-22 1984-06-05 Klaus Gersonde Method of and arrangement for producing lipid vesicles
JPS6058915A (ja) 1983-09-12 1985-04-05 Fujisawa Pharmaceut Co Ltd 薬物含有脂質小胞体製剤
US4744989A (en) 1984-02-08 1988-05-17 E. R. Squibb & Sons, Inc. Method of preparing liposomes and products produced thereby
US5736155A (en) 1984-08-08 1998-04-07 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US5077056A (en) 1984-08-08 1991-12-31 The Liposome Company, Inc. Encapsulation of antineoplastic agents in liposomes
US4830858A (en) 1985-02-11 1989-05-16 E. R. Squibb & Sons, Inc. Spray-drying method for preparing liposomes and products produced thereby
US4921757A (en) 1985-04-26 1990-05-01 Massachusetts Institute Of Technology System for delayed and pulsed release of biologically active substances
JPH0617309B2 (ja) 1985-11-29 1994-03-09 株式会社ビタミン研究所 アドリアマイシン包埋リポソ−ム製剤
DE3611229A1 (de) 1986-04-04 1987-10-08 Basf Ag Verfahren zur herstellung von feinverteilten, pulverfoermigen carotinoidpraeparaten
MX9203808A (es) 1987-03-05 1992-07-01 Liposome Co Inc Formulaciones de alto contenido de medicamento: lipido, de agentes liposomicos-antineoplasticos.
US5013556A (en) 1989-10-20 1991-05-07 Liposome Technology, Inc. Liposomes with enhanced circulation time
US5225212A (en) 1989-10-20 1993-07-06 Liposome Technology, Inc. Microreservoir liposome composition and method
US5766635A (en) 1991-06-28 1998-06-16 Rhone-Poulenc Rorer S.A. Process for preparing nanoparticles
DE69529054T2 (de) 1994-02-28 2003-08-21 Nanopharm Ag System zur gezielten wirkstoffzufuhr, verfahren zu seiner herstellung und verwendung
US5800833A (en) 1995-02-27 1998-09-01 University Of British Columbia Method for loading lipid vesicles
EP0825852B1 (en) 1995-04-18 2004-07-07 Yissum Research Development Company Of The Hebrew University Of Jerusalem Liposome drug-loading method and composition
US8137699B2 (en) 2002-03-29 2012-03-20 Trustees Of Princeton University Process and apparatuses for preparing nanoparticle compositions with amphiphilic copolymers and their use
US7850990B2 (en) 2001-10-03 2010-12-14 Celator Pharmaceuticals, Inc. Compositions for delivery of drug combinations
CA2462376C (en) 2001-10-03 2010-12-14 Celator Technologies Inc. Liposome loading with metal ions
CA2467064C (en) 2001-11-13 2011-02-08 Murray Webb Lipid carrier compositions with enhanced blood stability
LT2653465T (lt) * 2004-03-15 2016-09-12 Janssen Pharmaceutica Nv Opioidinio receptoriaus moduliatoriai
JP5001263B2 (ja) * 2005-05-20 2012-08-15 ドクター レディズ ラボラトリーズ (イーユー) リミテッド ジフェニルアラニン誘導体作製のための不斉水素化
GB201416186D0 (en) * 2014-09-12 2014-10-29 Redx Pharma Ltd Compounds
CN109503659B (zh) * 2019-01-03 2021-06-18 凯特立斯(深圳)科技有限公司 氧杂螺环双膦配体及其在α,β-不饱和羧酸不对称氢化中的应用

Also Published As

Publication number Publication date
EP4188923A1 (en) 2023-06-07
KR20230058630A (ko) 2023-05-03
CN116348465A (zh) 2023-06-27
CA3187393A1 (en) 2022-02-03
WO2022023450A1 (en) 2022-02-03
CN116348465B (zh) 2026-04-17
JP2023535595A (ja) 2023-08-18
JP7832924B2 (ja) 2026-03-18
MX2023001274A (es) 2023-04-24
US20220041595A1 (en) 2022-02-10
AU2021318923A1 (en) 2023-03-09
US20260049079A1 (en) 2026-02-19

Similar Documents

Publication Publication Date Title
IL300110A (en) Chiral synthesis of fused bicyclic raf inhibitors
SMT201600085B (it) Piperidin-4-il azetidin derivati come inibitori di jak1
HRP20180239T1 (hr) Deuterirani derivati benzokinolizina kao inhibitori vezikularnog monoaminskog transportera 2
SMT201700036B (it) Composti e composizioni come inibitori di protein chinasi
BR112015000232A8 (pt) Método para a síntese de ?,d-dihidroxi-isoleucina, composto, kit e método para sintetizar uma amatoxina
IL283959A (en) Substituted heterocycle fused gamma-carbolines synthesis
SMT201600275B (it) Composti eterociclici utili come inibitori di pdk1
HRP20160808T1 (hr) Kristalni paptidi epoksiketona kao inhibitori proteaze i sinteza ketoepoksidnih aminokiselina
SMP201000096B (it) Derivati tiazolici utilizzati come inibitori di pi3chinasi
ATE534294T1 (de) Verwendung von dithiin-tetracarboximiden zum bekämpfen phytopathogener pilze
DK3604510T3 (da) Antidoter til faktor-Xa-hæmmere og fremgangsmåder til anvendelse deraf
BRPI0911764A2 (pt) inibidores cíclicos de 11beta-hidroxiesteroide desigrogenase 1
EP2874606A4 (en) LIPOSOMAL COMPOSITIONS OF PROTEASOMBARS ON EPOXYKETONE BASE
DK1940839T3 (da) Pyridopyrimidione Inhibitors of P13Ka
EP2625242A4 (en) GRAPH-BASED MATERIAL FOR STABILIZING SLATE AND USE METHOD THEREFOR
DK2602089T3 (da) Resinform til nanotryk og fremgangsmåde til fremstilling deraf
EP2299999A4 (en) STAT3 INHIBITORS
PL2575778T3 (pl) KOMPOZYCJE FARMACEUTYCZNE KOKRYSZTAŁÓW TRAMADOLU i KOKSYBÓW
DK2379096T3 (da) TFPI-inhibitorer og fremgangsmåder til anvendelse
EP3913494C0 (en) DATA COMPRESSION TECHNIQUES
DK2625174T3 (da) Co-krystaller og salte af ccr3-inhibitorer
EP3402904A4 (en) SYNTHESIS OF BARCODING SEQUENCES USING PHASE SHIFT BLOCKS AND USES THEREOF
CY1110036T1 (el) Μεθοδος συνθεσης του ρανελικου στροντιου και των ενυδρων αλατων του
DK2285881T3 (da) Korn af polymer mikrogel og fremgangsmåde til fremstilling deraf
EP2609107C0 (en) PROCESS FOR THE SYNTHESIS OF OLIGORIBONUCLEOTIDES